Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
- Award ceiling
- Not stated
- Closes
- Sep 7, 2026
- Last verified
- 2026-10-09
Per-recipient award not stated for city or township governments, county governments, for profit organizations other than small businesses, independent school districts, native american tribal governments (federally recognized), native american tribal organizations (other than federally recognized tribal governments), nonprofits having a 501(c)(3) status with the irs, other than institutions of higher education, nonprofits that do not have a 501(c)(3) status with the irs, other than institutions of higher education, others (see text field entitled "additional information on eligibility" for clarification), private institutions of higher education, public and state controlled institutions of higher education, public housing authorities/indian housing authorities, small businesses, special district governments, state governments, closing Sep 7, 2026.
City or township governmentsCounty governmentsFor profit organizations other than small businessesIndependent school districtsNative American tribal governments (Federally recognized)Native American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)Private institutions of higher educationPublic and State controlled institutions of higher educationPublic housing authorities/Indian housing authoritiesSmall businessesSpecial district governmentsState governmentsEducationHealth & Human Services
In one sentence
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) does not state a per-recipient award amount, open to city or township governments, county governments, for profit organizations other than small businesses, independent…
Record fields
- Program pool (total)
- Not confirmedTotal across all awards in this programme. Not an amount any single applicant can receive.
- Award ceiling (per project)
- Not confirmed
- Award floor
- Not confirmed
- Typical award
- Not confirmed
- Deadline
- Sep 7, 2026
- Deadline type
- Fixed date
- Opens
- Nov 6, 2024
- Status
- Closed
- Eligible entities
- City or township governments · County governments · For profit organizations other than small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Small businesses · Special district governments · State governments
- Geography
- Not stated
- Matching funds
- No
- Disbursement
- Not confirmed
- Application effort
- Not confirmed
- Use of funds
- assay development for specific biological targets and disease mechanisms · screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches · hit validation, including implementation of secondary assays · hit-to-lead optimization
- Currency
- USD
How much money is available?
Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.
Program pool (total)Across all awards this cycle
Not statedAward ceiling (per project)The most one applicant can receive
Not statedWho can apply?
level
Derived from the source that published this record
entity
City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education
Source field: entity types+5more
, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governmentsindustry
Source field: industries
use
assay development for specific biological targets and disease mechanisms, hit validation, including implementation of secondary assays, hit-to-lead optimization, screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches
Source field: use of fundssize limit
Not confirmed
Source field: applicant size limitclause text
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government;…
We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.When does it close?
Sep 7, 2026ClosedDeadline type Fixed date
What can the money be used for?
4 categorysThe source’s own spending categories, and what is not parsed.
assay development for specific biological targets and disease mechanismsscreen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approacheshit validation, including implementation of secondary assayshit-to-lead optimization
These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.
How hard is the application?
1 fieldEffort, match requirement and reimbursement, as the source stated them.
- Application effort
- Not confirmed
- Disbursement
- Not confirmed
- Matching funds
- No
Who has received this funding?
4036 awardsAwards on file for this programme, counted rather than modelled.
4036 prior awards on file for this programme, largest first. Every row comes from the funder's own award listing; nothing here is estimated.
| Recipient | State | Amount | Fiscal year |
|---|---|---|---|
| RECOMBINATION THERAPEUTICS LLC | Not stated | $298,959 | 2020 |
| BRIDGENE BIOSCIENCES INC | Not stated | $298,928 | 2020 |
| VALITOR, INC. | Not stated | $298,514 | 2018 |
| RECOMBINETICS INC | Not stated | $297,931 | 2023 |
| XPOSE THERAPEUTICS, INC | Not stated | $297,741 | 2020 |
| SYNERGYS BIOTHERAPEUTICS INC | Not stated | $297,432 | 2019 |
| VARIGEN BIOSCIENCES CORP | Not stated | $297,088 | 2024 |
| BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | Not stated | $296,966 | 2022 |
| INHIPROT LLC | Not stated | $296,354 | 2017 |
| PACIFIC UNIVERSITY | Not stated | $296,009 | 2019 |
| CEDARS-SINAI MEDICAL CENTER | Not stated | $295,228 | 2022 |
| LOKI THERAPEUTICS, INC | Not stated | $294,962 | 2024 |
| CORD BLOOD PLUS, INC. | Not stated | $294,634 | 2019 |
| EXONANORNA LLC | Not stated | $294,528 | 2022 |
| IMMUNE MODULATORY THERAPIES LLC | Not stated | $293,173 | 2021 |
| DUKE UNIVERSITY | Not stated | $293,100 | 2020 |
| CRYOCRATE LLC | Not stated | $292,963 | 2025 |
| SONOVOL, INC | Not stated | $290,888 | 2019 |
| THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | Not stated | $289,781 | 2019 |
| KEVIRX INC. | Not stated | $289,307 | 2019 |
| NAVEGA THERAPEUTICS, INC. | Not stated | $288,284 | 2019 |
| OREGON HEALTH & SCIENCE UNIVERSITY | Not stated | $287,329 | 2021 |
| BLOOD CELL TECHNOLOGIES LLC | Not stated | $285,200 | 2023 |
| ERNEST PHARMACEUTICALS, INC. | Not stated | $284,249 | 2020 |
| OSEL, INC. | Not stated | $279,852 | 2025 |
| POP BIOTECHNOLOGIES INC | Not stated | $279,205 | 2018 |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | Not stated | $278,206 | 2018 |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | Not stated | $277,686 | 2022 |
| TRUSTEES OF INDIANA UNIVERSITY | Not stated | $276,996 | 2021 |
| IONCOLOGI INC | Not stated | $276,544 | 2025 |
| TERNALYS THERAPEUTICS, INC. | Not stated | $275,766 | 2022 |
| ARDAN PHARMA S.A.S. | Not stated | $275,243 | 2021 |
| REGULONIX LLC | Not stated | $274,040 | 2021 |
| TEL AVIV UNIVERSITY | Not stated | $274,006 | 2024 |
| NORTHWESTERN UNIVERSITY | Not stated | $271,614 | 2024 |
| ALPHATHERA, INC. | Not stated | $270,880 | 2020 |
| CURONBIOTECH INC | Not stated | $268,737 | 2019 |
| MOLECULAR THERANOSTICS LLC | Not stated | $265,179 | 2023 |
| IBIS REPRODUCTIVE HEALTH, INC. | Not stated | $264,839 | 2020 |
| OHIO STATE UNIVERSITY, THE | Not stated | $264,030 | 2024 |
| VIA THERAPEUTICS, LLC | Not stated | $263,895 | 2020 |
| VANDERBILT UNIVERSITY MEDICAL CENTER | Not stated | $260,852 | 2024 |
| ONCOTAB, INC. | Not stated | $260,588 | 2021 |
| GRADIENT MEDICAL INC. | Not stated | $259,549 | 2022 |
| LINK BIOSYSTEMS INC | Not stated | $258,073 | 2023 |
| FURMAN UNIVERSITY | Not stated | $256,129 | 2022 |
| COARE HOLDINGS INC | Not stated | $255,481 | 2018 |
| SAPIENCE THERAPEUTICS, INC. | Not stated | $255,240 | 2020 |
| LARIX BIOSCIENCE LLC | Not stated | $252,282 | 2021 |
| STINGINN, LLC | Not stated | $252,064 | 2020 |
| LUMIPHORE INC | Not stated | $251,985 | 2021 |
| VIA THERAPEUTICS, LLC | Not stated | $251,917 | 2021 |
| UNIVERSITÄT BASEL | Not stated | $251,385 | 2023 |
| CUREBIOTECH, INC. | Not stated | $250,804 | 2022 |
| UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | Not stated | $250,310 | 2023 |
| QUENCH MEDICAL INC. | Not stated | $249,815 | 2025 |
| MYOSIN THERAPEUTICS INC | Not stated | $249,417 | 2025 |
| ITHAX PHARMACEUTICALS INC | Not stated | $249,109 | 2020 |
| CALIFORNIA INSTITUTE OF TECHNOLOGY | Not stated | $249,000 | 2023 |
| CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY | Not stated | $249,000 | 2023 |
| FRED HUTCHINSON CANCER CENTER | Not stated | $249,000 | 2024 |
| THE GENERAL HOSPITAL CORPORATION | Not stated | $248,998 | 2025 |
| CULNEXIN THERAPEUTICS, INC. | Not stated | $246,118 | 2022 |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | Not stated | $245,220 | 2025 |
| TECHNOLOGY COMMERCIALIZATION PARTNERS LLC | Not stated | $243,144 | 2020 |
| ASYLIATX | Not stated | $241,407 | 2022 |
| OREGON HEALTH & SCIENCE UNIVERSITY | Not stated | $238,290 | 2000 |
| THE GENERAL HOSPITAL CORPORATION | Not stated | $236,853 | 2024 |
| GRANNUS THERAPEUTICS, INC. | Not stated | $233,195 | 2020 |
| BIOTHERAPEUTICS, INC. | Not stated | $230,729 | 2020 |
| UNIVERSITY OF FLORIDA | Not stated | $230,347 | 2021 |
| WAYPATH PHARMA LLC | Not stated | $225,000 | 2022 |
| NAMI THERAPEUTICS CORP | Not stated | $224,946 | 2019 |
| AVM BIOTECHNOLOGY, INC. | Not stated | $224,770 | 2020 |
| MIGRA-THERAPEUTICS, LLC | Not stated | $224,425 | 2019 |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | Not stated | $224,104 | 2024 |
| ERNEST PHARMACEUTICALS, INC. | Not stated | $223,594 | 2018 |
| SPECTRAGENETICS, INC. | Not stated | $222,717 | 2021 |
| HOSPITAL FOR SICK CHILDREN, THE | Not stated | $215,998 | 2023 |
| THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | Not stated | $214,930 | 2023 |
| TEZCAT BIOSCIENCES, INC. | Not stated | $209,986 | 2022 |
| COURIER THERAPEUTICS INC | Not stated | $204,365 | 2018 |
| NORTHEASTERN UNIVERSITY | Not stated | $200,000 | 2022 |
| ALGOMEDIX, INC. | Not stated | $198,195 | 2017 |
| ONCOSYNERGY, INC. | Not stated | $198,014 | 2019 |
| THE CHILDREN'S HOSPITAL OF PHILADELPHIA | Not stated | $197,518 | 2025 |
| SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | Not stated | $195,000 | 2021 |
| THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | Not stated | $193,926 | 2025 |
| TARGUT BIOTECHNOLOGIES INC | Not stated | $191,738 | 2022 |
| THE INSTITUTE FOR CANCER RESEARCH | Not stated | $187,000 | 2021 |
| THE INSTITUTE FOR CANCER RESEARCH | Not stated | $187,000 | 2020 |
| THE INSTITUTE FOR CANCER RESEARCH | Not stated | $187,000 | 2020 |
| THE INSTITUTE FOR CANCER RESEARCH | Not stated | $186,000 | 2025 |
| PROVINCIAL HEALTH SERVICES AUTHORITY | Not stated | $182,723 | 2018 |
| THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | Not stated | $180,950 | 2021 |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | Not stated | $178,893 | 2025 |
| DANA-FARBER CANCER INSTITUTE, INC. | Not stated | $178,000 | 2022 |
| DANA-FARBER CANCER INSTITUTE, INC. | Not stated | $178,000 | 2021 |
| THE GENERAL HOSPITAL CORPORATION | Not stated | $177,251 | 2018 |
| TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | Not stated | $177,209 | 2025 |
Recipient names as published by the California Grants Portal.
What comparable notices state
55 recordsStated ceilings on open records in the same industry.
Among open records stored under Education, 55 of 159 state an award ceiling. Those that do run:
- 25th percentile$172,750
- Median$375,000
- 75th percentile$600,000
A statistical estimate, not a prediction. It describes what a set of notices has published in this catalogue on the day you read it, and says nothing about what this programme will award. Records stating no ceiling are excluded rather than counted as zero, and the programme pool — what a funder has across every applicant — is a different column and is never mixed in.
Who has won this programme before?
4036 awardsAwards under the same assistance listing, not under this notice.
4036 federal awards on file under assistance listing 93.395, the programme this notice is published under. These are not awards made under this notice — a listing covers every year the programme runs, and awards under an open notice do not exist yet.
- $353,109,533PUBLIC HEALTH INSTITUTECA · FY2014
- $138,088,678OREGON HEALTH & SCIENCE UNIVERSITYOR · FY2014
- $135,357,649THE UNIVERSITY OF CHICAGOIL · FY2014
- $125,672,442NRG ONCOLOGY FOUNDATION INCPA · FY2014
- $115,346,605UNIVERSITY OF SOUTHERN CALIFORNIACA · FY2014
Common questions
5 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.
- When is the application deadline?
- Sep 7, 2026.
- Who is eligible to apply?
- City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governments.
- What can the funding be used for?
- assay development for specific biological targets and disease mechanisms, screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches, hit validation, including implementation of secondary assays, hit-to-lead optimization, as classified by the source.
- Is matching funding required?
- No. The source states that no matching funds are required.
- Has this programme funded anyone before?
- 4036 prior awards are on file for this programme, made by National Institutes of Health. Recipients, amounts and fiscal years are listed on this page.
AI summary of the source text
Optional. Every core field on this record is already above, free and complete.
AI summary of the source text
Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.
Included with Studio
Sign inWhat else is open
Also open from National Institutes of Health
- Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure – Clinical Coordinating Center (CCC) & Data Coordinating Center (DCC)Closes Not statedAwards Not stated
- NIH Stroke Clinical Trials Network (StrokeNet) Infrastructure – Regional Coordinating Stroke Centers (RCCs)Closes Not statedAwards Not stated
- Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation CenterCloses Not statedAwards Not stated
- Undiagnosed Diseases Network (UDN) Clinical and Data Coordinating CenterCloses Not statedAwards Not stated
- Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure – Clinical Research Sites (U24 Clinical Trial Not Allowed)Closes Not statedAwards Not stated
- Undiagnosed Diseases Network (UDN) Clinical Networks of Diagnostic ExcellenceCloses Not statedAwards Not stated
Also open under assistance listing 93.395
A listing names the programme; a notice names one round of it. These are other rounds open now, not other years of this one.
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)Closes Jan 11, 2027Awards up to $700,000
- Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)Closes Not statedAwards Not stated
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)Closes Jan 7, 2027Awards up to $500,000
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)Closes Jan 7, 2027Awards up to $375,000
- Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)Closes Sep 25, 2029Awards Not stated
- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)Closes Jan 7, 2028Awards Not stated
Provenance
Source pagegrants.gov
Retrieved2026-10-09
MethodAutomated check
First seen2026-09-04
Assistance listing93.395
The official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.